Clinical research priorities in Renal cell carcinoma : Renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designs—Workgroup No. 6
✍ Scribed by Kamal A. Hanash; Joseph W. Aquilina; David M. Barrett; Michael L. Blute; Abraham T. K. Cockett; Federico A. Corica; Gilda G. Hillman; Berton Zbar; Zhengping Zhuang
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 50 KB
- Volume
- 80
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
C hemoprevention refers to the prevention of cancer or reduction of risk in susceptible individuals by the administration of natural or synthetic drugs with minimal toxicity to suppress, delay, or reverse carcinogenesis. 1 Chemoprevention is most effective in the early stages of cancer formation when reversibility may be feasible. High risk target populations for renal cell carcinoma include patients with an inherited predisposition for this disease (von Hippel -Lindau [VHL] disease, hereditary papillary renal carcinoma, familial renal cell carcinoma) and sporadic cases such as acquired cystic kidney disease (patients undergoing dialysis). These patients may be candidates for a preventive strategy. Patients who have undergone radical nephrectomy for renal cell carcinoma who are at high risk for recurrence because of locally advanced disease or the presence of lymph node metastases also are good candidates for a preventive approach.
Experimental chemopreventive agents including nutritional supplements should be screened in animal models to determine their safety and efficacy for human use. For this goal the Eker rat model 2 * Workgroup participant.
is a good animal model because it is a hereditary form of spontaneous renal cell carcinoma in Wistar rats due to a single gene mutation that Presented at ''Diagnosis and Prognosis of Renal shares similarities with VHL disease. Additional experimental models Cell Carcinoma: 1997 Workshop,'' Rochester, should be developed to simulate the VHL gene mutation 3,4 as well as Minnesota, March 21-22, 1997.
other acquired and spontaneous variants of renal cell carcinoma.